Valneva, Pfizer Lyme vaccine application clears EMA validation step
PFE•EMA validation starts EU review of Pfizer-Valneva Lyme vaccine application
- EMA validated the marketing authorization application for Pfizer-Valneva’s Lyme disease vaccine candidate PF-07307405, starting its EU review.
- Filing based on Phase 3 VALOR data showing more than 70% efficacy; trial reported no safety concerns.
